Cancer Vaccines Market by Type (Preventive Vaccine and Therapeutic Vaccine), by Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Viral Vector & DNA Cancer Vaccine, and Whole-cell Cancer Vaccines), by Indication (Prostate Cancer, Cervical Cancer, and Others), and by End-user (Adult and Pediatric Vaccine) - Global Opportunity Analysis and Industry Forecast 2022-2030

Cancer Vaccines Market

Industry:  Life Sciences & Healthcare | Publish Date: Mar 2020 | No of Pages:  332 | No. Tables:  188 | No. Figures:  158

Market Definition:

The Cancer Vaccines Market was valued at USD 4.32 billion in 2021 and is predicted to reach USD 12.17 billion by 2030 with a CAGR of 12.2% from 2022-2030.

Cancer vaccines are a biological response modifier that stimulates the body’s immune system to fight against cancer. Currently, preventive and therapeutic vaccines are gaining momentum in the global market. Several vaccines have been approved in the past few years to prevent HPV infection, prostate, and other cancers. Besides, the highly crowded pipeline where vaccines are showcasing encouraging success in clinical trials across a wide range of cancers indicates a strong future for the market. Also, with continuous R&D activities in this field, researchers have developed other improved platforms for vaccine development, such as personalized neoantigen cancer vaccines, mRNA vaccines, stem cells, and others. However, these are in the early stages of development but represent a huge potential in the market. 

Market Dynamics and Trends:

A surge in the cases of HPV infections that leads to cervical cancer is expected to drive the demand for these vaccines. According to the World Health Organization (WHO), there were ~ 604 000 new cases and 342 000 deaths due to cervical cancer in 2020 globally. Among this, ~90% of new cases & deaths belonged to low- and middle-income nations. Also, new product development, extended approval to approved vaccines, and a rise in government initiatives are the other factors driving the growth.

For instance, the Health Ministry of Japan resumed recommending HPV vaccines to girls aged 12 to 16 years in March 2022. In June 2022, China’s NMPA approved a two-dose schedule for GSK’s HPV vaccine Cervarix in the girls aged 9-14 years for preventing cervical tumor. In addition, technological advancement in healthcare sectors, such as early diagnosis and vaccine delivery platforms including Liposomal Delivery Systems and Virosomes is further accelerating the market growth. Moreover, unhealthy dietary habits and consumption of tobacco that leads to tumor also increase the demand for these vaccines.

However, the presence of alternative therapies such as acupuncture, aromatherapy and longer timelines in manufacturing vaccines are among a few factors restraining the market growth. Conversely, approval of a new type of vaccines including TheraCys, TICE, and PROVENGE is projected to create new avenues for the market in the forecast period. 

Market Segmentations and Scope of the Study:

The cancer vaccines market is segmented based on technology, type, indication, end-user, and geography. Based on technology, the market is classified into Dendritic Cells (DC), Recombinant, Antigen/Adjuvant, Viral Vector & DNA, and Whole-cell Cancer Vaccines. Based on type, the market is bifurcated into preventive and therapeutic vaccines. Based on indication, the market is analyzed across prostate, cervical, and others. Based on end-user, the market is divided into adult and pediatric vaccines. Geographic breakdown and analysis of each of the aforesaid segments include regions comprising of North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis:

North America holds maximum share in the global market and is expected to continue its dominance throughout the forecast period. This is attributed to a rise in number of hospitals & diagnostic centers equipped with advanced medical facilities & technologies and high prevalence of disease in this region. As per the American Cancer Society, ~1.9 million new cases of cancer are expected to be diagnosed, and ~609,360 deaths are projected in 2022 in the U.S. Additionally, rise in the leading manufacturers are focusing on expanding their geographical presence that further boost the regional market. For instance, In June 2020, UbiVac collaborated with Bristol Myers to evaluate tolerability, efficacy and safety of its DPV-001 cancer vaccine product with Bristol’s anti-OX40 and Opdivo. This joint effort tests that this combination would support anticancer immunity in advanced triple negative breast cancer. 

On the other hand, Asia-Pacific is expected to show a steady rise owing to an increase in the geriatric population suffering from cancer, such as gastric & prostate cancer. For instance, in 2021, according to BMC, the incidence of gastric cancer was 64 per 100,000 among the population aged 50–59 years and 143 per 100,000 in people aged 60–69 years in China.  Also, development of the R&D sector in the field of oncology with an advancement of plasma therapies to treat this disease in countries such as China and India is further propelling the regional growth. For instance, in July 2021, the Chinese health authority NMPA’s Center for Drug Evaluation released new guidance on oncology R&D that directs the drug makers to focus on a patient-centric R&D approach, driving clinical trials and focusing research around areas of unmet needs.

Competitive Landscape:

Cancer vaccines market is comprised of various market players namely GlaxoSmithKline Plc., CSL Limited, Pfizer Inc., Bristol-Myers Squibb, AstraZeneca Plc., Sanofi, Vaccinogen Inc., The Sanpower Group, Moderna Inc., Merck & Co., Inc., and Astellas Pharma Inc. These manufacturers are actively involved in several strategies such as agreements and business expansions to further enhance their product portfolio and geographical reach.

For instance, in October 2022, Merck opted to jointly develop and market a personalized mRNA vaccine along with Moderna. Similarly, in November 2020, Moderna Inc. announced an expansion cohort of its ongoing Phase 1 study for its personalized cancer vaccine (PCV) mRNA-4157 in combination with Keytruda from Merck. The vaccine along with Keytruda is well tolerated at all dose levels and showed positive results for HPV(-) HNSCC patients, thereby expanding its application for Head and Neck Squamous Cell Carcinoma patients.

KEY BENEFITS:

  • The cancer vaccines market report provides the quantitative analysis of the current market and estimations through 2022-2030 that assists in identifying the prevailing market opportunities to capitalize on.

  • The study comprises a deep dive analysis of the cancer vaccines market trend including the current and future trends for depicting the prevalent investment pockets in the market.

  • The information related to key drivers, restraints and opportunities and their impact on the cancer vaccines market is provided in the report.

  • The competitive analysis of the market players along with their market share in the cancer vaccines market

  • The SWOT analysis and Porters Five Forces model is elaborated in the study.

  • Value chain analysis in the market study provides a clear picture of the stakeholders’ roles.

KEY MARKET SEGMENTS:

By Technology

  • Dendritic Cells (DC) Cancer Vaccines

  • Recombinant Cancer Vaccines

  • Antigen/Adjuvent Cancer Vaccines

  • Viral Vector and DNA Cancer Vaccines

  • Whole-cell Cancer Vaccines

By Type

  • Preventive Vaccine

  • Therapeutic Vaccine

By Indication

  • Prostate Cancer

  • Cervical Cancer

  • Others

By End-user

  • Adult Vaccines

  • Pediatric Vaccine

By Geography

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Rest of Europe

  • Asia-Pacific

    • China

    • India

    • Japan

    • Australia

    • Rest of Asia-Pacific

  • RoW

    • UAE

    • Saudi Arabia

    • South Africa

    • Brazil

    • Remaining Countries

1.... INTRODUCTION

1.1.           REPORT DESCRIPTION

1.2.           Research Methodology

1.2.1             Secondary Research

1.2.2             Data Analysis Framework

1.2.3             Market size estimation

1.2.4             Forecasting

1.2.5             Primary Research and Data Validation

2.... MARKET SNAPSHOT, 2019-2030 Million USD

2.1.           MARKET SNAPSHOT

3.... PORTER’S FIVE FORCE MODEL ANALYSIS

4.... MARKET DYNAMICS

4.1.           GROWTH DRIVERS

4.1.1             DRIVER 1

4.1.2             DRIVER 2

4.1.3             DRIVER 3

4.1.4             DRIVER 4

4.2.           CHALLENGES

4.2.1             CHALLENGE 1

4.2.2             CHALLENGE 2

4.3.           OPPORTUNITIES

4.3.1             OPPORTUNITY 1

4.3.2             OPPORTUNITY 2

5.... Global Cancer Vaccines Market, By Technology

5.1.           Overview

5.2.           Dendritic Cells (DC) Cancer Vaccines

5.2.1             Dendritic Cells (DC) Cancer Vaccines Market, By Region

5.2.1.1        North America Dendritic Cells (DC) Cancer Vaccines Market, By Country

5.2.1.2        Europe Dendritic Cells (DC) Cancer Vaccines Market, By Country

5.2.1.3        Asia-Pacific Dendritic Cells (DC) Cancer Vaccines Market, By Country

5.2.1.4        RoW Dendritic Cells (DC) Cancer Vaccines Market, By Country

5.3.           Recombinant Cancer Vaccines

5.3.1             Recombinant Cancer Vaccines Market, By Region

5.3.1.1        North America Recombinant Cancer Vaccines Market, By Country

5.3.1.2        Europe Recombinant Cancer Vaccines Market, By Country

5.3.1.3        Asia-Pacific Recombinant Cancer Vaccines Market, By Country

5.3.1.4        RoW Recombinant Cancer Vaccines Market, By Country

5.4.           Antigen/Adjuvent Cancer Vaccines

5.4.1             Antigen/Adjuvent Cancer Vaccines Market, By Region

5.4.1.1        North America Antigen/Adjuvent Cancer Vaccines Market, By Country

5.4.1.2        Europe Antigen/Adjuvent Cancer Vaccines Market, By Country

5.4.1.3        Asia-Pacific Antigen/Adjuvent Cancer Vaccines Market, By Country

5.4.1.4        RoW Antigen/Adjuvent Cancer Vaccines Market, By Country

5.5.           Viral Vector and DNA Cancer Vaccines

5.5.1             Viral Vector and DNA Cancer Vaccines Market, By Region

5.5.1.1        North America Viral Vector and DNA Cancer Vaccines Market, By Country

5.5.1.2        Europe Viral Vector and DNA Cancer Vaccines Market, By Country

5.5.1.3        Asia-Pacific Viral Vector and DNA Cancer Vaccines Market, By Country

5.5.1.4        RoW Viral Vector and DNA Cancer Vaccines Market, By Country

6.... Global Cancer Vaccines Market, By Type

6.1.           Overview

6.2.           Preventive Cancer Vaccines

6.2.1             Preventive Cancer Vaccines Market, By Region

6.2.1.1        North America Preventive Cancer Vaccines Market, By Country

6.2.1.2        Europe Preventive Cancer Vaccines Market, By Country

6.2.1.3        Asia-Pacific Preventive Cancer Vaccines Market, By Country

6.2.1.4        RoW Preventive Cancer Vaccines Market, By Country

6.3.           Therapeutic Cancer Vaccines

6.3.1             Therapeutic Cancer Vaccines Market, By Region

6.3.1.1        North America Therapeutic Cancer Vaccines Market, By Country

6.3.1.2        Europe Therapeutic Cancer Vaccines Market, By Country

6.3.1.3        Asia-Pacific Therapeutic Cancer Vaccines Market, By Country

6.3.1.4        RoW Therapeutic Cancer Vaccines Market, By Country

7.... Global Cancer Vaccines Market, By Indication

7.1.           Overview

7.2.           Cervical Cancer

7.2.1             Cervical Cancer Market, By Region

7.2.1.1        North America Cervical Cancer Market, By Country

7.2.1.2        Europe Cervical Cancer Market, By Country

7.2.1.3        Asia-Pacific Cervical Cancer Market, By Country

7.2.1.4        RoW Cervical Cancer Market, By Country

7.3.           Prostate Cancer

7.3.1             Prostate Cancer Market, By Region

7.3.1.1        North America Prostate Cancer Market, By Country

7.3.1.2        Europe Prostate Cancer Market, By Country

7.3.1.3        Asia-Pacific Prostate Cancer Market, By Country

7.3.1.4        RoW Prostate Cancer Market, By Country

7.4.           Other Indications

7.4.1             Other Indications Market, By Region

7.4.1.1        North America Other Indications Market, By Country

7.4.1.2        Europe Other Indications Market, By Country

7.4.1.3        Asia-Pacific Other Indications Market, By Country

7.4.1.4        RoW Other Indications Market, By Country

8.... Global Cancer Vaccines Market, By End User

8.1.           Overview

8.2.           Pediatrics

8.2.1             Pediatrics Market, By Region

8.2.1.1        North America Pediatrics Market, By Country

8.2.1.2        Europe Pediatrics Market, By Country

8.2.1.3        Asia-Pacific Pediatrics Market, By Country

8.2.1.4        RoW Pediatrics Market, By Country

8.3.           Adults

8.3.1             Adults Market, By Region

8.3.1.1        North America Adults Market, By Country

8.3.1.2        Europe Adults Market, By Country

8.3.1.3        Asia-Pacific Adults Market, By Country

8.3.1.4        RoW Adults Market, By Country

9.... Global Cancer Vaccines Market, By Region

9.1.           Overview

9.2.           North America

9.2.1             North America Cancer Vaccines Market, By Technology

9.2.2             North America Cancer Vaccines Market, By Type

9.2.3             North America Cancer Vaccines Market, By Indication

9.2.4             North America Cancer Vaccines Market, By End User

9.2.5             North America Cancer Vaccines, Market By Country

9.2.5.1        U.S.

9.2.5.1.1        U.S. Cancer Vaccines Market, By Technology

9.2.5.1.2        U.S. Cancer Vaccines Market, By Type

9.2.5.1.3        U.S. Cancer Vaccines Market, By Indication

9.2.5.1.4        U.S. Cancer Vaccines Market, By End User

9.2.5.2        Canada

9.2.5.2.1        Canada Cancer Vaccines Market, By Technology

9.2.5.2.2        Canada Cancer Vaccines Market, By Type

9.2.5.2.3        Canada Cancer Vaccines Market, By Indication

9.2.5.2.4        Canada Cancer Vaccines Market, By End User

9.2.5.3        Mexico

9.2.5.3.1        Mexico Cancer Vaccines Market, By Technology

9.2.5.3.2        Mexico Cancer Vaccines Market, By Type

9.2.5.3.3        Mexico Cancer Vaccines Market, By Indication

9.2.5.3.4        Mexico Cancer Vaccines Market, By End User

9.3.           Europe

9.3.1             Europe Cancer Vaccines Market, By Technology

9.3.2             Europe Cancer Vaccines Market, By Type

9.3.3             Europe Cancer Vaccines Market, By Indication

9.3.4             Europe Cancer Vaccines Market, By End User

9.3.5             Europe Cancer Vaccines, Market By Country

9.3.5.1        Germany

9.3.5.1.1        Germany Cancer Vaccines Market, By Technology

9.3.5.1.2        Germany Cancer Vaccines Market, By Type

9.3.5.1.3        Germany Cancer Vaccines Market, By Indication

9.3.5.1.4        Germany Cancer Vaccines Market, By End User

9.3.5.2        UK

9.3.5.2.1        UK Cancer Vaccines Market, By Technology

9.3.5.2.2        UK Cancer Vaccines Market, By Type

9.3.5.2.3        UK Cancer Vaccines Market, By Indication

9.3.5.2.4        UK Cancer Vaccines Market, By End User

9.3.5.3        France

9.3.5.3.1        France Cancer Vaccines Market, By Technology

9.3.5.3.2        France Cancer Vaccines Market, By Type

9.3.5.3.3        France Cancer Vaccines Market, By Indication

9.3.5.3.4        France Cancer Vaccines Market, By End User

9.3.5.4        Italy

9.3.5.4.1        Italy Cancer Vaccines Market, By Technology

9.3.5.4.2        Italy Cancer Vaccines Market, By Type

9.3.5.4.3        Italy Cancer Vaccines Market, By Indication

9.3.5.4.4        Italy Cancer Vaccines Market, By End User

9.3.5.5        Rest of Europe

9.3.5.5.1        Rest of Europe Cancer Vaccines Market, By Technology

9.3.5.5.2        Rest of Europe Cancer Vaccines Market, By Type

9.3.5.5.3        Rest of Europe Cancer Vaccines Market, By Indication

9.3.5.5.4        Rest of Europe Cancer Vaccines Market, By End User

9.4.           Asia-Pacific

9.4.1             Asia-Pacific Cancer Vaccines Market, By Technology

9.4.2             Asia-Pacific Cancer Vaccines Market, By Type

9.4.3             Asia-Pacific Cancer Vaccines Market, By Indication

9.4.4             Asia-Pacific Cancer Vaccines Market, By End User

9.4.5             Asia-Pacific Cancer Vaccines, Market By Country

9.4.5.1        China

9.4.5.1.1        China Cancer Vaccines Market, By Technology

9.4.5.1.2        China Cancer Vaccines Market, By Type

9.4.5.1.3        China Cancer Vaccines Market, By Indication

9.4.5.1.4        China Cancer Vaccines Market, By End User

9.4.5.2        India

9.4.5.2.1        India Cancer Vaccines Market, By Technology

9.4.5.2.2        India Cancer Vaccines Market, By Type

9.4.5.2.3        India Cancer Vaccines Market, By Indication

9.4.5.2.4        India Cancer Vaccines Market, By End User

9.4.5.3        Japan

9.4.5.3.1        Japan Cancer Vaccines Market, By Technology

9.4.5.3.2        Japan Cancer Vaccines Market, By Type

9.4.5.3.3        Japan Cancer Vaccines Market, By Indication

9.4.5.3.4        Japan Cancer Vaccines Market, By End User

9.4.5.4        Australia

9.4.5.4.1        Australia Cancer Vaccines Market, By Technology

9.4.5.4.2        Australia Cancer Vaccines Market, By Type

9.4.5.4.3        Australia Cancer Vaccines Market, By Indication

9.4.5.4.4        Australia Cancer Vaccines Market, By End User

9.4.5.5        Rest of Asia-Pacific

9.4.5.5.1        Rest of Asia-Pacific Cancer Vaccines Market, By Technology

9.4.5.5.2        Rest of Asia-Pacific Cancer Vaccines Market, By Type

9.4.5.5.3        Rest of Asia-Pacific Cancer Vaccines Market, By Indication

9.4.5.5.4        Rest of Asia-Pacific Cancer Vaccines Market, By End User

9.5.           RoW

9.5.1             RoW Cancer Vaccines Market, By Technology

9.5.2             RoW Cancer Vaccines Market, By Type

9.5.3             RoW Cancer Vaccines Market, By Indication

9.5.4             RoW Cancer Vaccines Market, By End User

9.5.5             RoW Cancer Vaccines, Market By Country

9.5.5.1        Brazil

9.5.5.1.1        Brazil Cancer Vaccines Market, By Technology

9.5.5.1.2        Brazil Cancer Vaccines Market, By Type

9.5.5.1.3        Brazil Cancer Vaccines Market, By Indication

9.5.5.1.4        Brazil Cancer Vaccines Market, By End User

9.5.5.2        Argentina

9.5.5.2.1        Argentina Cancer Vaccines Market, By Technology

9.5.5.2.2        Argentina Cancer Vaccines Market, By Type

9.5.5.2.3        Argentina Cancer Vaccines Market, By Indication

9.5.5.2.4        Argentina Cancer Vaccines Market, By End User

9.5.5.3        Turkey

9.5.5.3.1        Turkey Cancer Vaccines Market, By Technology

9.5.5.3.2        Turkey Cancer Vaccines Market, By Type

9.5.5.3.3        Turkey Cancer Vaccines Market, By Indication

9.5.5.3.4        Turkey Cancer Vaccines Market, By End User

9.5.5.4        South Africa

9.5.5.4.1        South Africa Cancer Vaccines Market, By Technology

9.5.5.4.2        South Africa Cancer Vaccines Market, By Type

9.5.5.4.3        South Africa Cancer Vaccines Market, By Indication

9.5.5.4.4        South Africa Cancer Vaccines Market, By End User

9.5.5.5        Rest of RoW

9.5.5.5.1        Rest of RoW Cancer Vaccines Market, By Technology

9.5.5.5.2        Rest of RoW Cancer Vaccines Market, By Type

9.5.5.5.3        Rest of RoW Cancer Vaccines Market, By Indication

9.5.5.5.4        Rest of RoW Cancer Vaccines Market, By End User

10.. COMPANY PROFILES

10.1.         Advaxis Inc.

10.1.1           COMPANY OVERVIEW

10.1.2           COMPANY SNAPSHOT

10.1.3           OPERATING BUSINESS SEGMENTS

10.1.4           PRODUCT PORTFOLIO

10.1.5           BUSINESS PERFORMANCE

10.1.6           KEY STRATEGIC MOVES AND DEVELOPMENT

10.2.         Amgen Inc.

10.2.1           COMPANY OVERVIEW

10.2.2           COMPANY SNAPSHOT

10.2.3           OPERATING BUSINESS SEGMENTS

10.2.4           PRODUCT PORTFOLIO

10.2.5           BUSINESS PERFORMANCE

10.2.6           KEY STRATEGIC MOVES AND DEVELOPMENT

10.3.         Dynavax Technologies Corporation

10.3.1           COMPANY OVERVIEW

10.3.2           COMPANY SNAPSHOT

10.3.3           OPERATING BUSINESS SEGMENTS

10.3.4           PRODUCT PORTFOLIO

10.3.5           BUSINESS PERFORMANCE

10.3.6           KEY STRATEGIC MOVES AND DEVELOPMENT

10.4.         Generex Biotechnology Corporation

10.4.1           COMPANY OVERVIEW

10.4.2           COMPANY SNAPSHOT

10.4.3           OPERATING BUSINESS SEGMENTS

10.4.4           PRODUCT PORTFOLIO

10.4.5           BUSINESS PERFORMANCE

10.4.6           KEY STRATEGIC MOVES AND DEVELOPMENT

10.5.         GlaxoSmithKline plc (GSK)

10.5.1           COMPANY OVERVIEW

10.5.2           COMPANY SNAPSHOT

10.5.3           OPERATING BUSINESS SEGMENTS

10.5.4           PRODUCT PORTFOLIO

10.5.5           BUSINESS PERFORMANCE

10.5.6           KEY STRATEGIC MOVES AND DEVELOPMENT

10.6.         Immunocellular Therapeutics, Ltd

10.6.1           COMPANY OVERVIEW

10.6.2           COMPANY SNAPSHOT

10.6.3           OPERATING BUSINESS SEGMENTS

10.6.4           PRODUCT PORTFOLIO

10.6.5           BUSINESS PERFORMANCE

10.6.6           KEY STRATEGIC MOVES AND DEVELOPMENT

10.7.         Merck & Co., Inc.

10.7.1           COMPANY OVERVIEW

10.7.2           COMPANY SNAPSHOT

10.7.3           OPERATING BUSINESS SEGMENTS

10.7.4           PRODUCT PORTFOLIO

10.7.5           BUSINESS PERFORMANCE

10.7.6           KEY STRATEGIC MOVES AND DEVELOPMENT

10.8.         Sanpower Group Co. Ltd. (Dendereon Corporation)

10.8.1           COMPANY OVERVIEW

10.8.2           COMPANY SNAPSHOT

10.8.3           OPERATING BUSINESS SEGMENTS

10.8.4           PRODUCT PORTFOLIO

10.8.5           BUSINESS PERFORMANCE

10.8.6           KEY STRATEGIC MOVES AND DEVELOPMENT

10.9.         UbiVac

10.9.1           COMPANY OVERVIEW

10.9.2           COMPANY SNAPSHOT

10.9.3           OPERATING BUSINESS SEGMENTS

10.9.4           PRODUCT PORTFOLIO

10.9.5           BUSINESS PERFORMANCE

10.9.6           KEY STRATEGIC MOVES AND DEVELOPMENT

10.10.       Vaccinogen, Inc.

10.10.1         COMPANY OVERVIEW

10.10.2         COMPANY SNAPSHOT

10.10.3         OPERATING BUSINESS SEGMENTS

10.10.4         PRODUCT PORTFOLIO

10.10.5         BUSINESS PERFORMANCE

10.10.6         KEY STRATEGIC MOVES AND DEVELOPMENT

LIST OF TABLES

TABLE 1.         Global Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 2.         Dendritic Cells (DC) Cancer Vaccines Market Value, By Region, 2019-2030, Million USD

TABLE 3.         North America Dendritic Cells (DC) Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 4.         Europe Dendritic Cells (DC) Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 5.         Asia-Pacific Dendritic Cells (DC) Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 6.         RoW Dendritic Cells (DC) Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 7.         Recombinant Cancer Vaccines Market Value, By Region, 2019-2030, Million USD

TABLE 8.         North America Recombinant Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 9.         Europe Recombinant Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 10.       Asia-Pacific Recombinant Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 11.       RoW Recombinant Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 12.       Antigen/Adjuvent Cancer Vaccines Market Value, By Region, 2019-2030, Million USD

TABLE 13.       North America Antigen/Adjuvent Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 14.       Europe Antigen/Adjuvent Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 15.       Asia-Pacific Antigen/Adjuvent Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 16.       RoW Antigen/Adjuvent Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 17.       Viral Vector and DNA Cancer Vaccines Market Value, By Region, 2019-2030, Million USD

TABLE 18.       North America Viral Vector and DNA Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 19.       Europe Viral Vector and DNA Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 20.       Asia-Pacific Viral Vector and DNA Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 21.       RoW Viral Vector and DNA Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 22.       Global Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 23.       Preventive Cancer Vaccines Market Value, By Region, 2019-2030, Million USD

TABLE 24.       North America Preventive Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 25.       Europe Preventive Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 26.       Asia-Pacific Preventive Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 27.       RoW Preventive Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 28.       Therapeutic Cancer Vaccines Market Value, By Region, 2019-2030, Million USD

TABLE 29.       North America Therapeutic Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 30.       Europe Therapeutic Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 31.       Asia-Pacific Therapeutic Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 32.       RoW Therapeutic Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

TABLE 33.       Global Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 34.       Cervical Cancer Market Value, By Region, 2019-2030, Million USD

TABLE 35.       North America Cervical Cancer Market Value, By Country, 2019-2030, Million USD

TABLE 36.       Europe Cervical Cancer Market Value, By Country, 2019-2030, Million USD

TABLE 37.       Asia-Pacific Cervical Cancer Market Value, By Country, 2019-2030, Million USD

TABLE 38.       RoW Cervical Cancer Market Value, By Country, 2019-2030, Million USD

TABLE 39.       Prostate Cancer Market Value, By Region, 2019-2030, Million USD

TABLE 40.       North America Prostate Cancer Market Value, By Country, 2019-2030, Million USD

TABLE 41.       Europe Prostate Cancer Market Value, By Country, 2019-2030, Million USD

TABLE 42.       Asia-Pacific Prostate Cancer Market Value, By Country, 2019-2030, Million USD

TABLE 43.       RoW Prostate Cancer Market Value, By Country, 2019-2030, Million USD

TABLE 44.       Other Indications Market Value, By Region, 2019-2030, Million USD

TABLE 45.       North America Other Indications Market Value, By Country, 2019-2030, Million USD

TABLE 46.       Europe Other Indications Market Value, By Country, 2019-2030, Million USD

TABLE 47.       Asia-Pacific Other Indications Market Value, By Country, 2019-2030, Million USD

TABLE 48.       RoW Other Indications Market Value, By Country, 2019-2030, Million USD

TABLE 49.       Global Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 50.       Pediatrics Market Value, By Region, 2019-2030, Million USD

TABLE 51.       North America Pediatrics Market Value, By Country, 2019-2030, Million USD

TABLE 52.       Europe Pediatrics Market Value, By Country, 2019-2030, Million USD

TABLE 53.       Asia-Pacific Pediatrics Market Value, By Country, 2019-2030, Million USD

TABLE 54.       RoW Pediatrics Market Value, By Country, 2019-2030, Million USD

TABLE 55.       Adults Market Value, By Region, 2019-2030, Million USD

TABLE 56.       North America Adults Market Value, By Country, 2019-2030, Million USD

TABLE 57.       Europe Adults Market Value, By Country, 2019-2030, Million USD

TABLE 58.       Asia-Pacific Adults Market Value, By Country, 2019-2030, Million USD

TABLE 59.       RoW Adults Market Value, By Country, 2019-2030, Million USD

TABLE 60.       Global Cancer Vaccines Market Value, By Region, 2019-2030, Million USD

TABLE 61.       North America Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 62.       North America Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 63.       North America Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 64.       North America Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 65.       U.S. Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 66.       U.S. Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 67.       U.S. Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 68.       U.S. Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 69.       Canada Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 70.       Canada Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 71.       Canada Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 72.       Canada Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 73.       Mexico Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 74.       Mexico Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 75.       Mexico Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 76.       Mexico Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 77.       Europe Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 78.       Europe Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 79.       Europe Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 80.       Europe Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 81.       Germany Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 82.       Germany Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 83.       Germany Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 84.       Germany Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 85.       UK Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 86.       UK Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 87.       UK Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 88.       UK Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 89.       France Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 90.       France Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 91.       France Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 92.       France Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 93.       Italy Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 94.       Italy Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 95.       Italy Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 96.       Italy Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 97.       Rest of Europe Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 98.       Rest of Europe Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 99.       Rest of Europe Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 100.    Rest of Europe Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 101.    Asia-Pacific Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 102.    Asia-Pacific Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 103.    Asia-Pacific Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 104.    Asia-Pacific Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 105.    China Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 106.    China Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 107.    China Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 108.    China Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 109.    India Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 110.    India Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 111.    India Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 112.    India Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 113.    Japan Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 114.    Japan Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 115.    Japan Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 116.    Japan Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 117.    Australia Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 118.    Australia Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 119.    Australia Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 120.    Australia Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 121.    Rest of Asia-Pacific Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 122.    Rest of Asia-Pacific Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 123.    Rest of Asia-Pacific Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 124.    Rest of Asia-Pacific Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 125.    RoW Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 126.    RoW Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 127.    RoW Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 128.    RoW Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 129.    Brazil Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 130.    Brazil Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 131.    Brazil Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 132.    Brazil Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 133.    Argentina Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 134.    Argentina Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 135.    Argentina Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 136.    Argentina Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 137.    Turkey Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 138.    Turkey Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 139.    Turkey Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 140.    Turkey Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 141.    South Africa Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 142.    South Africa Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 143.    South Africa Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 144.    South Africa Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 145.    Rest of RoW Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

TABLE 146.    Rest of RoW Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

TABLE 147.    Rest of RoW Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

TABLE 148.    Rest of RoW Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

TABLE 149.    Advaxis Inc.: COMPANY SNAPSHOT

TABLE 150.    Advaxis Inc.: OPERATING SEGMENTS

TABLE 151.    Advaxis Inc.: PRODUCT PORTFOLIO

TABLE 152.    Advaxis Inc.: KEY STRATERGY

TABLE 153.    Amgen Inc.: COMPANY SNAPSHOT

TABLE 154.    Amgen Inc.: OPERATING SEGMENTS

TABLE 155.    Amgen Inc.: PRODUCT PORTFOLIO

TABLE 156.    Amgen Inc.: KEY STRATERGY

TABLE 157.    Dynavax Technologies Corporation: COMPANY SNAPSHOT

TABLE 158.    Dynavax Technologies Corporation: OPERATING SEGMENTS

TABLE 159.    Dynavax Technologies Corporation: PRODUCT PORTFOLIO

TABLE 160.    Dynavax Technologies Corporation: KEY STRATERGY

TABLE 161.    Generex Biotechnology Corporation: COMPANY SNAPSHOT

TABLE 162.    Generex Biotechnology Corporation: OPERATING SEGMENTS

TABLE 163.    Generex Biotechnology Corporation: PRODUCT PORTFOLIO

TABLE 164.    Generex Biotechnology Corporation: KEY STRATERGY

TABLE 165.    GlaxoSmithKline plc (GSK): COMPANY SNAPSHOT

TABLE 166.    GlaxoSmithKline plc (GSK): OPERATING SEGMENTS

TABLE 167.    GlaxoSmithKline plc (GSK): PRODUCT PORTFOLIO

TABLE 168.    GlaxoSmithKline plc (GSK): KEY STRATERGY

TABLE 169.    Immunocellular Therapeutics, Ltd: COMPANY SNAPSHOT

TABLE 170.    Immunocellular Therapeutics, Ltd: OPERATING SEGMENTS

TABLE 171.    Immunocellular Therapeutics, Ltd: PRODUCT PORTFOLIO

TABLE 172.    Immunocellular Therapeutics, Ltd: KEY STRATERGY

TABLE 173.    Merck & Co., Inc.: COMPANY SNAPSHOT

TABLE 174.    Merck & Co., Inc.: OPERATING SEGMENTS

TABLE 175.    Merck & Co., Inc.: PRODUCT PORTFOLIO

TABLE 176.    Merck & Co., Inc.: KEY STRATERGY

TABLE 177.    Sanpower Group Co. Ltd. (Dendereon Corporation): COMPANY SNAPSHOT

TABLE 178.    Sanpower Group Co. Ltd. (Dendereon Corporation): OPERATING SEGMENTS

TABLE 179.    Sanpower Group Co. Ltd. (Dendereon Corporation): PRODUCT PORTFOLIO

TABLE 180.    Sanpower Group Co. Ltd. (Dendereon Corporation): KEY STRATERGY

TABLE 181.    UbiVac: COMPANY SNAPSHOT

TABLE 182.    UbiVac: OPERATING SEGMENTS

TABLE 183.    UbiVac: PRODUCT PORTFOLIO

TABLE 184.    UbiVac: KEY STRATERGY

TABLE 185.    Vaccinogen, Inc.: COMPANY SNAPSHOT

TABLE 186.    Vaccinogen, Inc.: OPERATING SEGMENTS

TABLE 187.    Vaccinogen, Inc.: PRODUCT PORTFOLIO

TABLE 188.    Vaccinogen, Inc.: KEY STRATERGY

 

 

LIST OF FIGURES

FIGURE 1.       Global Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 2.       Dendritic Cells (DC) Cancer Vaccines Market Value, By Region, 2019-2030, Million USD

FIGURE 3.       North America Dendritic Cells (DC) Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 4.       Europe Dendritic Cells (DC) Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 5.       Asia-Pacific Dendritic Cells (DC) Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 6.       RoW Dendritic Cells (DC) Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 7.       Recombinant Cancer Vaccines Market Value, By Region, 2019-2030, Million USD

FIGURE 8.       North America Recombinant Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 9.       Europe Recombinant Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 10.     Asia-Pacific Recombinant Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 11.     RoW Recombinant Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 12.     Antigen/Adjuvent Cancer Vaccines Market Value, By Region, 2019-2030, Million USD

FIGURE 13.     North America Antigen/Adjuvent Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 14.     Europe Antigen/Adjuvent Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 15.     Asia-Pacific Antigen/Adjuvent Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 16.     RoW Antigen/Adjuvent Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 17.     Viral Vector and DNA Cancer Vaccines Market Value, By Region, 2019-2030, Million USD

FIGURE 18.     North America Viral Vector and DNA Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 19.     Europe Viral Vector and DNA Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 20.     Asia-Pacific Viral Vector and DNA Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 21.     RoW Viral Vector and DNA Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 22.     Global  Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 23.     Preventive Cancer Vaccines Market Value, By Region, 2019-2030, Million USD

FIGURE 24.     North America Preventive Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 25.     Europe Preventive Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 26.     Asia-Pacific Preventive Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 27.     RoW Preventive Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 28.     Therapeutic Cancer Vaccines Market Value, By Region, 2019-2030, Million USD

FIGURE 29.     North America Therapeutic Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 30.     Europe Therapeutic Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 31.     Asia-Pacific Therapeutic Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 32.     RoW Therapeutic Cancer Vaccines Market Value, By Country, 2019-2030, Million USD

FIGURE 33.     Global Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 34.     Cervical Cancer Market Value, By Region, 2019-2030, Million USD

FIGURE 35.     North America Cervical Cancer Market Value, By Country, 2019-2030, Million USD

FIGURE 36.     Europe Cervical Cancer Market Value, By Country, 2019-2030, Million USD

FIGURE 37.     Asia-Pacific Cervical Cancer Market Value, By Country, 2019-2030, Million USD

FIGURE 38.     RoW Cervical Cancer Market Value, By Country, 2019-2030, Million USD

FIGURE 39.     Prostate Cancer Market Value, By Region, 2019-2030, Million USD

FIGURE 40.     North America Prostate Cancer Market Value, By Country, 2019-2030, Million USD

FIGURE 41.     Europe Prostate Cancer Market Value, By Country, 2019-2030, Million USD

FIGURE 42.     Asia-Pacific Prostate Cancer Market Value, By Country, 2019-2030, Million USD

FIGURE 43.     RoW Prostate Cancer Market Value, By Country, 2019-2030, Million USD

FIGURE 44.     Other Indications Market Value, By Region, 2019-2030, Million USD

FIGURE 45.     North America Other Indications Market Value, By Country, 2019-2030, Million USD

FIGURE 46.     Europe Other Indications Market Value, By Country, 2019-2030, Million USD

FIGURE 47.     Asia-Pacific Other Indications Market Value, By Country, 2019-2030, Million USD

FIGURE 48.     RoW Other Indications Market Value, By Country, 2019-2030, Million USD

FIGURE 49.     Global Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 50.     Pediatrics Market Value, By Region, 2019-2030, Million USD

FIGURE 51.     North America Pediatrics Market Value, By Country, 2019-2030, Million USD

FIGURE 52.     Europe Pediatrics Market Value, By Country, 2019-2030, Million USD

FIGURE 53.     Asia-Pacific Pediatrics Market Value, By Country, 2019-2030, Million USD

FIGURE 54.     RoW Pediatrics Market Value, By Country, 2019-2030, Million USD

FIGURE 55.     Adults Market Value, By Region, 2019-2030, Million USD

FIGURE 56.     North America Adults Market Value, By Country, 2019-2030, Million USD

FIGURE 57.     Europe Adults Market Value, By Country, 2019-2030, Million USD

FIGURE 58.     Asia-Pacific Adults Market Value, By Country, 2019-2030, Million USD

FIGURE 59.     RoW Adults Market Value, By Country, 2019-2030, Million USD

FIGURE 60.     Global  Cancer Vaccines Market Value, By Region, 2019-2030, Million USD

FIGURE 61.     North America Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 62.     North America Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 63.     North America Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 64.     North America Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 65.     U.S. Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 66.     U.S. Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 67.     U.S. Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 68.     U.S. Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 69.     Canada Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 70.     Canada Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 71.     Canada Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 72.     Canada Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 73.     Mexico Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 74.     Mexico Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 75.     Mexico Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 76.     Mexico Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 77.     Europe Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 78.     Europe Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 79.     Europe Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 80.     Europe Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 81.     Germany Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 82.     Germany Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 83.     Germany Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 84.     Germany Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 85.     UK Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 86.     UK Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 87.     UK Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 88.     UK Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 89.     France Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 90.     France Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 91.     France Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 92.     France Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 93.     Italy Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 94.     Italy Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 95.     Italy Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 96.     Italy Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 97.     Rest of Europe Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 98.     Rest of Europe Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 99.     Rest of Europe Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 100.  Rest of Europe Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 101.  Asia-Pacific Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 102.  Asia-Pacific Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 103.  Asia-Pacific Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 104.  Asia-Pacific Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 105.  China Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 106.  China Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 107.  China Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 108.  China Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 109.  India Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 110.  India Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 111.  India Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 112.  India Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 113.  Japan Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 114.  Japan Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 115.  Japan Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 116.  Japan Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 117.  Australia Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 118.  Australia Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 119.  Australia Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 120.  Australia Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 121.  Rest of Asia-Pacific Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 122.  Rest of Asia-Pacific Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 123.  Rest of Asia-Pacific Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 124.  Rest of Asia-Pacific Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 125.  RoW Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 126.  RoW Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 127.  RoW Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 128.  RoW Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 129.  Brazil Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 130.  Brazil Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 131.  Brazil Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 132.  Brazil Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 133.  Argentina Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 134.  Argentina Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 135.  Argentina Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 136.  Argentina Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 137.  Turkey Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 138.  Turkey Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 139.  Turkey Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 140.  Turkey Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 141.  South Africa Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 142.  South Africa Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 143.  South Africa Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 144.  South Africa Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 145.  Rest of RoW Cancer Vaccines Market Value, By Technology, 2019-2030, Million USD

FIGURE 146.  Rest of RoW Cancer Vaccines Market Value, By Type, 2019-2030, Million USD

FIGURE 147.  Rest of RoW Cancer Vaccines Market Value, By Indication, 2019-2030, Million USD

FIGURE 148.  Rest of RoW Cancer Vaccines Market Value, By End User, 2019-2030, Million USD

FIGURE 149.  Advaxis Inc.: NET SALES,2017-2019

FIGURE 150.  Amgen Inc.: NET SALES,2017-2019

FIGURE 151.  Dynavax Technologies Corporation: NET SALES,2017-2019

FIGURE 152.  Generex Biotechnology Corporation: NET SALES,2017-2019

FIGURE 153.  GlaxoSmithKline plc (GSK): NET SALES,2017-2019

FIGURE 154.  Immunocellular Therapeutics, Ltd: NET SALES,2017-2019

FIGURE 155.  Merck & Co., Inc.: NET SALES,2017-2019

FIGURE 156.  Sanpower Group Co. Ltd. (Dendereon Corporation): NET SALES,2017-2019

FIGURE 157.  UbiVac: NET SALES,2017-2019

FIGURE 158.  Vaccinogen, Inc.: NET SALES,2017-2019

KEY PLAYERS

  • GlaxoSmithKline Plc

  • CSL Limited

  • Pfizer Inc.

  • Bristol-Myers Squibb

  • AstraZeneca Plc.

  • Sanofi

  • Vaccinogen Inc.

  • The Sanpower Group

  • Moderna Inc.

  • Merck & Co. Inc.

  • Astellas Pharma Inc.


Frequently Asked Questions
What will be the worth of cancer vaccines market by the end of 2030?

Global cancer vaccines market size is predicted to reach USD 12.17 billion by 2030 with a CAGR of 12.2% from 2022-2030.

Which region is expected to hold the highest market share in cancer vaccines industry?

North America holds maximum share in the global market. This is attributed to a rise in number of hospitals & diagnostic centers equipped with advanced medical facilities & technologies and high prevalence of disease in this region.

Which are the top players in the cancer vaccines market?

GlaxoSmithKline Plc., CSL Limited, Pfizer Inc., Bristol-Myers Squibb, AstraZeneca Plc., Sanofi, Vaccinogen Inc., The Sanpower Group, Moderna Inc., Merck & Co., Inc., and Astellas Pharma Inc.

What are the market segments and scope of the study?

The cancer vaccines market is segmented on the basis of technology, type, indication, end-user, and geography.

What are the challenges in the cancer vaccines market?

The presence of alternative therapies such as acupuncture, aromatherapy and longer timelines in manufacturing vaccines are among a few factors restraining the market growth.